Our research

Neurochlore is developing an innovative therapeutic strategy to improve Autism Spectrum Disorders (ASD).

The treatment developed by Neurochlore acts on the mechanisms causing Autism Spectrum Disorders. A first phase of research made it possible to highlight an imbalance in the level of chloride in the neurons, which could be at the origin of these disorders. In order to regulate this chloride level, a molecule was tested : bumetanide.

This drug candidate, tested by Neurochlore over the past ten years, is a diuretic already on the market. The repositioning of this drug for the treatment of Autism Spectrum Disorders allows a significant perspective on the safety of the molecule.

Administered as a syrup, Bumetanide is undergoing a phase III clinical trial. Neurochlore has already successfully conducted a monocentric study (60 children) as well as a phase II clinical trial which took place in six French centers (88 children). With an international patent for the use of this syrup in the treatment of Autism Spectrum Disorders, Neurochlore has joined forces with its partner Les Laboratoires Servier in an international randomized phase III double-blind study. If it is conclusive, it will make it possible to apply for registration with the health authorities in 2022 and then have a medicine on the market.

References :

Lemonnier et al., Translational Psychiatry, 2012

Lemonnier et al., Translational Psychiatry, 2017